Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

I) PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR OF THE COMPANY; AND II) PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR OF THE COMPANY

I. PROPOSED APPOINTMENT OF AN EXECUTIVE DIRECTOR OF THE COMPANY

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is hereby made to the announcement of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**") dated 1 March 2026, at which it was considered and approved to propose the appointment of Mr. Liu Daping (劉大平先生) ("**Mr. Liu**") as an executive director of the 11th session of the Board, and to recommend the same to the annual general meeting of the Company for consideration and approval. As the the Company will hold a board meeting on 23 April 2026 to carry out the work relating to the election of the 12th session of the Board, for the purpose of facilitating the overall board election arrangements, optimising the corporate governance structure and ensuring a smooth and orderly transition of the Board of the Company (the "**Board**"), the Board resolved to withdraw the aforesaid proposal for the nomination of Mr. Liu as an executive director of the 11th session of the Board and to change the same to the proposed nomination of Mr. Liu as an executive Director of the 12th session of the Board.

The Board of the Company is pleased to announce that, upon nomination by the Nomination Committee of the Board and consideration and approval at the Board, it is proposed to appoint Mr. Liu as an executive director of the 12th session of the Board. The proposed appointment is subject to approval by way of an ordinary resolution at the annual general meeting of the Company. The term of office of Mr. Liu will commence from the date of approval at the annual general meeting and will end upon the expiry of the term of the 12th session of the Board.

The biographical of Mr. Liu is set as follows:

Mr. Liu Daping, aged 39, currently serves as the Vice President of the Company. He graduated from China Pharmaceutical University (中國藥科大學) with a bachelor's degree in pharmaceutics. He currently serves as director and senior management in certain subsidiaries of the Group, including Livzon Pharmaceutical Research Institute of Livzon Group (麗珠集團麗珠醫藥研究所) and Livzon Pharmaceutical Factory of Livzon Group (麗珠集團麗珠制藥廠). From September 2010 to July 2019, he successively served as a technician, workshop director and production director of Shenzhen Haibin Pharmaceutical Co., Ltd. (深圳市海濱制藥有限公司). From July 2019 to June 2021, he served as the Executive Deputy General Manager of Shenzhen TaiTai Pharmaceutical Co., Ltd. (深圳太太藥業有限公司) From July 2021 to January 2024, he served as the Deputy Director of the Production Management Center of Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司), overseeing Shenzhen TaiTai Pharmaceutical Co., Ltd. (serving as General Manager from October 2021 to January 2024) and Joincare Haibin Pharmaceutical Co., Ltd. (健康元海濱藥業有限公司). He has served as the Vice President of the Company since January 2024. As at the date of this announcement, Mr. Liu does not hold any shares of the Company.

Upon the appointment of Mr. Liu taking effect after approval at the annual general meeting of the Company, the Company will enter into a director's service contract with Mr. Liu. Mr. Liu will serve as an executive director and concurrently as the President of the Company. He will receive an annual director's fee of RMB96,000 (pre-tax) during his term of office, and will also receive remuneration for his service as the President of the Company. The director's fee and remuneration of Mr. Liu have been determined by the Board with reference to his duties and responsibilities in the Company, the Company's remuneration policy and the market salary range for the position.

Save as disclosed above, Mr. Liu confirmed: (1) he has not held any directorship in any other listed companies in the past three years, nor does he have any other major appointments or professional qualifications; (2) he does not hold any other position in the Company or any member of the Group; (3) he has no relationship with any director, supervisor, senior management, major shareholder or controlling shareholder of the Company or any of its subsidiaries; and (4) as at the date of this announcement, he does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

II. PROPOSED APPOINTMENT OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR OF THE COMPANY

The Board of the Company is pleased to announce that, upon nomination by the Nomination Committee of the Board and consideration and approval at the meeting of the Board, it is proposed to appoint Ms. Kang Li (康立女士) ("**Ms. Kang**") as an independent non-executive director of the 12th session of the Board, to fill the vacancy arising from the departure of Mr. Bai Hua, an independent non-executive director of the Company, whose term of office as a director is about to expire upon reaching six years.

The appointment of Ms. Kang as an independent non-executive director of the Company is subject to approval by the shareholders of the Company at the annual general meeting. The qualifications and independence of Ms. Kang are subject to the filing review by the Shenzhen Stock Exchange with no objection, after which the annual general meeting may proceed with the voting.

The term of office of Ms. Kang will commence from the date of approval at the annual general meeting and will end upon the expiry of the term of the 12th session of the Board.

The biographical of Mr. Liu is set as follows:

Ms. Kang Li, aged 53, holds Chinese nationality and has no right of permanent residence overseas. She holds a Doctorate degree in Economics and is a certified public accountant. She has been a visiting scholar at the Berlin School of Economics and Law (德國柏林財經學院) and the Berlin University of Applied Sciences and Technology in Germany (柏林應用科技大學), and a visiting scholar at the University of West Georgia in the United States (美國西喬治亞大學). She served as a teaching assistant and lecturer at the School of Finance of Zhongnan University of Economics and Law (中南財經政法大學), an independent director of Weini Health (Shenzhen) Co., Ltd. (維尼健康（深圳）股份有限公司), and an independent director of Shenzhen CDL Precision Technology Co., Ltd. (深圳市智動力精密技術股份有限公司). She currently serves as an associate professor at the School of Finance of Zhongnan University of Economics and Law (中南財經政法大學), and an independent director of Hunan Haohua Chemical Co., Ltd. (湖南昊華化工股份有限公司) (a non-listed company), Shandong Sito Bio-technology Co., Ltd. (山東賽托生物科技股份有限公司) (300583.SZ), and Wuhan Zhongke Tongda High-tech Co., Ltd. (武漢中科通達高新技術股份有限公司) (688038.SH). As at the date of this announcement, Ms. Kang does not hold any shares of the Company.

As at the date of this announcement, Ms. Kang has confirmed that she meets the independence criteria set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Hong Kong Listing Rules"). Save as disclosed in this announcement, Ms. Kang (i) has not held any directorship in any other listed companies at present or within the three years prior to the date of this announcement; (ii) does not hold any other position in the Group; (iii) does not have any relationship with any other director, supervisor, senior management, major shareholder or controlling shareholder of the Company; and (iv) does not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Upon her appointment, Ms. Kang will receive an annual director's fee of RMB120,000 (pre-tax) during her term of office. The director's fee has been determined with reference to her duties and responsibilities in the Company, the Company's remuneration policy and the market salary range for such positions.

Save as disclosed above, there are no other matters concerning the proposed appointment of Ms. Kang as an independent non-executive director of the Company that need to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed under any of the paragraphs (h) to (v) of Rule 13.51(2) of the Hong Kong Listing Rules.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
23 April 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

* *For identification purpose only*